


BeiGene Product Portfolio and Pipeline

Three marketed products in China, three late-stage assets, seven early-stage clinical assets



	ASSETS	PROGRAMS	DOSE ESC.		DOSE EXPANSION		PIVOTAL		FILED	COMMERCIAL RIGHTS	
			PH1a	PH1b	PH2*	PH2**	PH3				
Internally Developed	zanubrutinib (BTK)	monotherapy + GAZYVA® (CD20)	R/R MCL, R/R CLL/SLL (NDAs accepted)								Global
			R/R WM								
			WM, 1L CLL/SLL, R/R CLL/SLL								
			R/R MZL								
			R/R FL								
	tislelizumab (PD-1)	monotherapy + chemo + pamiparib (PARP) + zanubrutinib (BTK)	R/R cHL, 2L+ UC (NDAs accepted)								Global
			2L NSCLC, 1L HCC, 2L ESCC								
			2L/3L HCC								
			R/R NK/T-cell lymphoma								
			1L Sq. NSCLC, 1L Non-Sq. NSCLC, 1L NPC, 1L SCLC								
			1L GC, 1L ESCC								
	pamiparib (PARP)	monotherapy + TMZ (chemo) + RT/TMZ (RT/chemo)	Solid tumors								Global
			B-cell malignancies								
			1L platinum-sensitive GC maintenance								
			2L platinum-sensitive OC maintenance								
3L gBRCA+ OC											
lifirafenib (RAF Dimer)	monotherapy	Solid tumors								Global	
		B-Raf- or K-RAS/N-RAS-mutated solid tumors									
		B-Raf- or K-RAS/N-RAS-mutated solid tumors									
BGB-A333 (PD-L1)	monotherapy & + tislelizumab	Solid tumors								Global	
		Solid tumors									
Collaborations	REVLIMID® (IMiD)	(albumin-bound paclitaxel)	R/R MM (marketed), NDMM (marketed), R/R NHL (Ph3)								China
			Breast cancer (marketed), Metastatic pancreatic cancer (filed)								
	VIDAZA® (hypomethylating agent)	(multi-kinase inhibitor) ¹	MDS, AML with 20-30% bone marrow blasts, CMML (marketed)								China
			NSCLC, RCC, OC, Melanoma, HCC/GEJ								
	ZW25	(bispecific HER2 antibody) ²	Planned (in Ph2 ex-China by Zymeworks)								Asia ex-Japan, NZ, AU
	ZW49	(bispecific anti-HER2 ADC) ²	Planned (in Ph1 ex-China by Zymeworks)								Asia ex-Japan, NZ, AU
	avadomide	(CC-122, CELMoD)	Planned (in Ph1b ex-China by Celgene)								China

*Some indications will not require a non-pivotal Ph2 clinical trial prior to beginning pivotal Ph2 or Ph3 clinical trials. **Confirmatory clinical trials post approval are required for accelerated approvals. ***REVLIMID® approved as a combination therapy with dexamethasone. 1.Collaboration with Mirati Therapeutics, Inc; APAC study; 2. Collaboration with Zymeworks

